Allarity Therapeutics, Inc. Servicing Liability at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions
Allarity Therapeutics, Inc. (ALLR) reported Servicing Liability at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions of $474.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-05-17.
Discontinued › Notes › Disclosure of Servicing Liabilities at Fair Value
us-gaap:ServicingLiabilityAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions · last filed 2022-11-14
- Allarity Therapeutics, Inc. servicing liability at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for the quarter ending 2021-12-31 was $0.00.
- Allarity Therapeutics, Inc. servicing liability at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for the quarter ending 2021-09-30 was $0.00.
- Allarity Therapeutics, Inc. servicing liability at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for the quarter ending 2021-06-30 was $273.00K.
- Allarity Therapeutics, Inc. servicing liability at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for the quarter ending 2021-03-31 was $201.00K.
- Allarity Therapeutics, Inc. servicing liability at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for fiscal 2021 was $474.00K, a 17.28% decline from fiscal 2020.
- Allarity Therapeutics, Inc. servicing liability at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for fiscal 2020 was $573.00K.
| Period end | Servicing Liability at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 3 month | Servicing Liability at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 6 month | Servicing Liability at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 9 month | Servicing Liability at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-17 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $273.00K derived: sum of 3 quarters · filed 2022-11-14 | $474.00K 10-K · filed 2022-05-17 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $273.00K derived: sum of 2 quarters · filed 2022-11-14 | $474.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $474.00K 10-Q · filed 2022-10-07 | ||
| 2021-03-31 | $201.00K 10-Q · filed 2022-05-27 | |||
| 2020-12-31 | $573.00K 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |